Blog Read the latest perspectives from our team of subject matter experts and others FDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Diversity & Inclusion Drug Development Global Impact HCP Volunteers KOL Engagement Provider Data Research Post Industries:Commercialization Global Impact Payors Pharmaceutical & Biotechnology Provider Data Research Sorry! No posts found for the applied filter.